Detailed Narrative
Strong Full Year FY25 Performance Driven by Bio-Fuels and Potable Spirits
India Glycols reported a robust full year FY25, with net sales growing 14% to INR 3,767 crores and standalone EBITDA increasing 23% to INR 521 crores. The Bio-Fuels segment was a standout, more than doubling its revenue by 103.7% to INR 1,044 crores, while Potable Spirits grew 22.8% to INR 1,163 crores. The joint venture also contributed significantly, with its net profit nearly tripling to INR 46.4 crores from INR 16.66 crores in the previous year.
Q4 FY25 Mixed Performance with Margin Expansion
Q4 FY25 saw a 7% decline in net sales to INR 863 crores compared to INR 924 crores in Q4 FY24. However, EBITDA for the quarter surged 32% to INR 145 crores from INR 109 crores in the prior year. Potable Spirits EBIT margins notably improved from 16.2% to 27.6%, and Bio-based Specialties and Performance Chemicals (BSPC) EBIT margins expanded by 368 basis points to 11.4%.
Strategic Expansion in Potable Spirits with Premiumization Focus
The company is aggressively pursuing premiumization in its IMFL business through a partnership with Amrut, launching brands like Amrut MaQintosh Black Label (priced at INR 1,100) and Amrut White Label. Significant inroads have been made in UP, Uttarakhand, and Delhi, with plans to expand into at least three more states in FY26. India Glycols is also a top 3 supplier to paramilitary forces and has secured approvals for its Soulmate whiskey and Zumba Limon brands in CSD, ensuring stable business and all-India reach.
Bio-Fuels Segment Benefits from Government Mandates
The Bio-Fuels business continues to thrive, supported by the government's ethanol blending program, which achieved 14.6% blending in FY24 against a 15% target and aims for 20% in FY26. The government's focus on energy independence and farmer income ensures continued support, with plans to potentially increase blending to 25-30% by 2030. The company has invested in grain-based capacities, with 750 crore liters of ethanol now coming from grain out of a total 1,150 crore liters, and expects a 25-30% increase in Indian corn production this year.
Chemicals and Biopharma Segments Face Headwinds but Strategize for Value
The Bio-based Specialties and Performance Chemicals (BSPC) segment saw a 17.6% decline in net revenue to INR 1,342 crores for FY25, though its EBIT margin improved by 91 basis points to 9.3%. Ennature Biopharma's top line grew by approximately 7% but faced significant pricing pressure due to softer international demand and increased competition. Both segments are focusing on moving up the value chain, developing branded products, and securing certifications like the US FDA Establishment Inspection Report for nutraceuticals.
Debt Management and Capex Outlook
India Glycols holds approximately INR 1,200 crores in long-term debt, with INR 500 crores allocated to the Chemical division and INR 700 crores to the Liquor division post-demerger. The company expects to repay INR 150-160 crores annually from the Spirits division and INR 90 crores from Chemicals. Major capex cycles, including the grain distillery, are largely complete, with no significant new capex planned until the demerger, apart from maintenance and ongoing projects.